source
- Scribe Therapeutics files for Nasdaq IPO, testing market appetite for early-stage gene-editing firmsScribe Therapeutics announced it has filed a registration statement to list its shares on the Nasdaq, marking the company’s first step toward a public offering. The filing highlights the growing i…
- Colorado judge blocks 70% price cap on Amgen's Enbrel, citing potential economic injuryA U.S. District Court in Colorado issued a preliminary injunction that stops a state‑imposed 70% price cap on Amgen's autoimmune drug Enbrel. The ruling was made by Judge Daniel Domenico, who grant…